title: Sorafenib in thyroid cancer patients: learning from toxicity.
authors: Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Cochin Hospital, AP-HP, Paris Descartes University, Paris, France.
authors: Olivier
authors: O
authors: Huillard
authors: Pharmacokinetics and Pharmacochemistry Unit, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Cochin Hospital, AP-HP, Paris Descartes University, Paris, France.
authors: Benoit
authors: B
authors: Blanchet
authors: Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Cochin Hospital, AP-HP, Paris Descartes University, Paris, France.
authors: Pascaline
authors: P
authors: Boudou-Rouquette
authors: Pharmacokinetics and Pharmacochemistry Unit, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Cochin Hospital, AP-HP and UMR 8638 CNRS, Faculty of Pharmacy, Paris Pharmaceutical Research Center, Paris Descartes University, Paris, France.
authors: Audrey
authors: A
authors: Thomas-Schoemann
authors: Medical Oncology Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre et Marie Curie University, Paris, France.
authors: Johanna
authors: J
authors: Wassermann
authors: Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Cochin Hospital, AP-HP, Paris Descartes University, Paris, France.
authors: François
authors: F
authors: Goldwasser
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide